Top entities: Myriad Genetics, Levi & Korsinsky, Ben Wheeler, Sam Raha, Joseph E. Levi.

What category does this event fall under?

Regulatory — classified as securities investigation.

What is the sentiment of coverage?

Aggregate sentiment score: -40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Aug 06, 2026. Coverage continues to evolve.

Regulatory securities investigation

Myriad Genetics Securities Investigation

Q: When did this event occur?

First reported Aug 03, 2026; last updated Aug 06, 2026.

Q: What is the market impact?

General. Myriad Genetics shares fell following the revenue miss and guidance cut, reflecting investor disappointment and heightened regulatory risk.

Q: What were the key actions taken?

Myriad Genetics reported revenue · Levi & Korsinsky commenced investigation Myriad Genetics · Myriad Genetics suspended EBITDA guidance

Analysis based on 15 articles · First reported Aug 03, 2026 · Last updated Aug 06, 2026

Sentiment

-40

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

Myriad Genetics shares fell following the revenue miss and guidance cut, reflecting investor disappointment and heightened regulatory risk. The investigation could lead to securities litigation and potential financial penalties, further pressuring the stock.

biotechnology healthcare

Event Summary

Levi & Korsinsky, a securities litigation firm, commenced an investigation into Myriad Genetics, Inc. (Nasdaq: MYGN) for potential violations of federal securities laws. The investigation centers on Myriad's May 5, 2026 reaffirmation of full-year 2026 revenue guidance of $860-$880 million, which was later cut to $770-$790 million in early August 2026, a reduction of approximately $90 million at the midpoint. The company also suspended its adjusted EBITDA guidance of $37-$49 million. Myriad reported Q2 2026 revenue of approximately $190.7 million, down 11% year-over-year and 7-8% below consensus, attributing the shortfall to reimbursement pressure, collections issues, lower average revenue per test, and weaker prenatal performance. The investigation aims to determine whether Myriad made materially false or misleading statements regarding its financial outlook.

Key Actions

95 Myriad Genetics reported revenue

85 Levi & Korsinsky commenced investigation Myriad Genetics

80 Myriad Genetics suspended EBITDA guidance

Entities Involved

stock

Myriad Genetics

Myriad Genetics is the subject of the investigation; its stock fell after reporting weak Q2 results and cutting guidance, and it faces potential securities litigation.

Importance 100.0 Sentiment -60.0

priv

Levi & Korsinsky

Levi & Korsinsky initiated the investigation, positioning itself to represent investors and potentially recover losses.

Importance 80.0 Sentiment 20.0

per

Ben Wheeler

Ben Wheeler, CFO, reaffirmed guidance on May 5, 2026, which is now under scrutiny; his statements are central to the investigation.

Importance 40.0 Sentiment -30.0

per

Sam Raha

Sam Raha, CEO, also reaffirmed guidance and expected sequential growth, which did not materialize; his statements are part of the investigation.

Importance 40.0 Sentiment -30.0

per

Joseph E. Levi

Joseph E. Levi is a partner at Levi & Korsinsky and a contact for investors seeking to participate in the investigation.

Importance 30.0 Sentiment 10.0

exch

Nasdaq

Nasdaq is the exchange where Myriad Genetics is listed; the investigation does not directly affect Nasdaq.

Importance 10.0 Sentiment 0.0

Relationships

Levi & Korsinsky related ↔ Joseph E. Levi

Levi & Korsinsky related ↔ Nasdaq

Joseph E. Levi related ↔ Nasdaq

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard